CHHE (China Health Industries Holdings) Research & Development: $0.00 Mil (TTM As of Mar. 2024)


CHHE China Health Industries Holdings Inc CHHE
20 GF Score
Price $0.00
View Full Analysis

What is China Health Industries Holdings Research & Development?

China Health Industries Holdings CHHE 20 Research & Development is $0.00 Mil as of Mar. 2024. GuruFocus rates CHHE with a GF Score™ of 20/100.

Research & Development is the aggregate amount of research and development expenses during the year. China Health Industries Holdings's Research & Development for the three months ended in Mar. 2024 was $0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.

China Health Industries Holdings  (OTCPK:CHHE) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

China Health Industries Holdings Research & Development Related Terms

China Health Industries Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for China Health Industries Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Health Industries Holdings Research & Development Chart

China Health Industries Holdings Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

China Health Industries Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CHHE
20GF Score
China Health Industries Holdings Inc CHHE
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China Health Industries Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.00 Mil mean?
China Health Industries Holdings (CHHE) has a Research & Development of $0.00 Mil as of Mar. 2024. Research and development expense is the total cost for research and development activities. View historical data on China Health Industries Holdings and its competitors.
Is China Health Industries Holdings' Research & Development too high?
China Health Industries Holdings' current Research & Development is $0.00 Mil. Overall, China Health Industries Holdings has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does China Health Industries Holdings' Research & Development compare to BIOE and CRYM?
China Health Industries Holdings' Research & Development of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on China Health Industries Holdings and its competitors. China Health Industries Holdings's current Research & Development is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Health Industries Holdings stock overvalued right now?
China Health Industries Holdings (CHHE) has a current Research & Development of $0.00 Mil. The current Research & Development is $0.00 Mil. China Health Industries Holdings' overall GF Score™ is 20/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For China Health Industries Holdings (CHHE), the current Research & Development is $0.00 Mil as of Mar. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

China Health Industries Holdings Business Description

Address 3199-1 Longxiang Road, Songbei District, Heilongjiang Province, Harbin, CHN, 150028
China Health Industries Holdings Inc operates in the health product industry and produces, markets and distributes medicines, health products, health devices and cosmetics. Its products series cover hemp-based food, hemp-based medicines, external used medicines and health food. The company has segmented its operating activities into three reportable segments, Humankind, HLJ Huimeijia, and Others. It generates maximum revenue from the Humankind segment.
20GF Score

Get the complete analysis for CHHE

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price